Mary Sain
Internal Medicine · Little Rock, ARNPI 1104860824
Payments from drug & device makers
Across 131 payments — averaging $13.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$437
- Johnson & Johnson$315
- Amarin Pharma, Inc.$153
- E.r. Squibb & Sons, L.L.C.$115
- Novartis$76
- Boehringer Ingelheim$73
- plus $649 from 24 others
What the payments were for
- Food & beverage$1,816100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 33 | $437 |
| Johnson & Johnson | 24 | $315 |
| Amarin Pharma, Inc. | 9 | $153 |
| E.r. Squibb & Sons, L.L.C. | 9 | $115 |
| Novartis | 6 | $76 |
| Boehringer Ingelheim | 5 | $73 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $67 |
| Pfizer | 5 | $64 |
| Merck | 4 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $49 |
| Boston Scientific | 3 | $42 |
| Exact Sciences | 2 | $36 |
| Astellas Pharma US Inc | 2 | $33 |
| Amneal Pharmaceuticals LLC | 2 | $32 |
| Arbor Pharmaceuticals, Inc. | 2 | $32 |
| Novo Nordisk | 2 | $29 |
| Abbott | 1 | $24 |
| Bardy Diagnostics, Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $16 |
| GSK | 1 | $16 |
| Bayer | 1 | $15 |
| Shield Therapeutics Inc | 1 | $15 |
| AbbVie | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
| Eisai Inc. | 1 | $13 |
| Acella Pharmaceuticals, LLC | 1 | $13 |
| Nevro Corp. | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $12 |
How this compares
$1,816 in reported general payments places this provider in the 75th percentile of 614 internal medicine providers in Arkansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Potassium Chloride | 25 | $606 |
| Atorvastatin Calcium | 26 | $269 |
| Levothyroxine Sodium | 34 | $232 |
| Lisinopril | 23 | $202 |
| Rosuvastatin Calcium | 25 | $190 |
| Raloxifene Hcl | 13 | $175 |
| Amlodipine Besylate | 27 | $174 |
| Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid | 15 | $79 |
| Meloxicam | 12 | $75 |
| Simvastatin | 12 | $59 |
| Hydrochlorothiazide | 14 | $39 |
| Cyclobenzaprine Hcl | 13 | $9 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $32 | $23234 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 614 internal medicine providers in Arkansas.
Other internal medicine in Little Rock
- Priyantha WijewardaneLittle Rock$43.6M
- Joseph RoseLittle Rock$1.1M
- Alexander KaczenskiLittle Rock$305K
- Manisha SinghLittle Rock$71K
- Srikanth VallurupalliLittle Rock$34K
- Aaron StrobelLittle Rock$32K
- Jeremy DavisLittle Rock$17K
- Ritesh RampureLittle Rock$13K
- Milton RoachLittle Rock$12K
- Michael CloudLittle Rock$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.